Useful Links
New Study Provides Most Comprehensive Overview of Genetic Test Development, Usage and Spending
From – Diagnostic Testing & Emerging Technologies
As might be expected, there has been rapid growth in genetic test availability and spending on these tests since 2014. But, comprehensive new collaborative analysis conducted by…
G2 Blog
Diagnostic danger in the lab: Time to reform how we process orders
By Oleg Bess, M.D. bio
I don’t know about you, but I was stunned by the findings from a recent report published by Coverys, a national liability insurer, which I feel should…
Compliance Perspectives: The 12 Things to Include in Your Drug & Alcohol Testing Policy
From – G2 Compliance Advisor
No! No! No! The truth is that state laws on marijuana use and possession have little to no direct impact on workplace drug policies and the testing methods used…
PAMA Reimbursement: CMS Explains How to Get ADLT Status for New Lab Tests
From – National Intelligence Report
Although the 2018 market-based Clinical Laboratory Fee Schedule (CLFS) is officially in effect, implementation of the new PAMA Part B payment rules for lab tests remains…
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
From – Laboratory Industry Report
The pace of deal making has picked up a bit, but deal volume remains relatively low on both the M&A and strategic alliance fronts. As usual, smaller molecular and genomics firms are…
DX Earnings Report: PAMA Cuts Make Little Dent on Q1 Lab Earnings
From – National Intelligence Report
One quarter into its existence, the new PAMA Medicare Part B fee schedule seems to be having only a marginal impact on at least publicly traded labs. In fact, the recently published…